Krish Patel, MD is a clinical investigator, Director of the Lymphoma Program, and Director of Hematologic Malignancies and Cellular Therapy at the Swedish Cancer Institute (SCI) in Seattle, Washington.   In 2016, he joined the Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy as a specialist in the care of patients with lymphomas and CLL. 

In early 2022, Dr. Patel was named the Director of Hematologic Malignancies and Cellular Therapy to oversee the continued growth of SCI’s clinical and research programs in all hematologic diseases and broader strategy in growth of cellular therapy, including applications of cellular therapy in solid tumor malignancies.

Clinically, Dr. Patel specializes in all aspects of care of patients with lymphomas and CLL and is a specialist in the therapeutic use of cellular and non-cellular immunotherapies.  He has a specific research focus in the early stage development of novel targeted agents, immunotherapies, and engineered cellular therapies to advance care for patients with lymphoid malignancies.   He is a principal investigator for numerous therapeutic clinical trials at SCI, with a focus on phase I and II studies in lymphomas, CLL, and cellular therapies.  Dr. Patel is also a member of the Paul G. Allen Research Center at SCI, serving as a co-founding member of the Center for Immuno-oncology.